# Immunogenicity of COVID-19 Vaccine Co-administration With Influenza Vaccine in Healthy Volunteers

> **NCT06831786** · EARLY_PHASE1 · COMPLETED · sponsor: **Prince of Songkla University** · enrollment: 36 (actual)

## Conditions studied

- COVID - 19

## Interventions

- **BIOLOGICAL:** Bivalent mRNA SARS-CoV-2 vaccine
- **BIOLOGICAL:** Quardrivalent influenza vaccine

## Key facts

- **NCT ID:** NCT06831786
- **Lead sponsor:** Prince of Songkla University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-03-01
- **Primary completion:** 2024-05-31
- **Final completion:** 2024-05-31
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2025-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06831786

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06831786, "Immunogenicity of COVID-19 Vaccine Co-administration With Influenza Vaccine in Healthy Volunteers". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06831786. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*